Stanley R Riddell

List of Publications by Year in Descending Order

85 papers	15,295 citations	50 h-index	88 g-index
88 ext. papers	18,348 ext. citations	11.5 avg, IF	6.53 L-index

#	Paper	IF	Citations
85	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.. *Journal of Clinical Oncology*, **2022**, JCO2101755	2.2	4
84	Synthetic HLA-independent T cell receptors for cancer immunotherapy.. *Cancer Cell*, **2022**, 40, 359-361	24.3	
83	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. *Science Translational Medicine*, **2021**, 13, eaba6006	17.5	3
82	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. *Blood*, **2021**, 137, 323-335	2.2	39
81	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. *Cancer Cell*, **2021**, 39, 193-208.e10	24.3	50
80	Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer. *Nature Medicine*, **2021**, 27, 1339-1341	50.5	2
79	Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. *Science Signaling*, **2021**, 14,	8.8	11
78	Synthetic receptors for logic gated T cell recognition and function. *Current Opinion in Immunology*, **2021**, 74, 9-17	7.8	1
77	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. *Blood*, **2020**, 135, 1650-1660	2.2	115
76	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. *Blood*, **2020**, 136, 37-38	2.2	4
75	Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. *Blood Cancer Discovery*, **2020**, 1, 130-133	7	3
74	Designed protein logic to target cells with precise combinations of surface antigens. *Science*, **2020**, 369, 1637-1643	33.3	48
73	Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors. *Clinical Cancer Research*, **2019**, 25, 7506-7516	12.9	23
72	Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. *Blood*, **2019**, 134, 1585-1597	2.2	120
71	Tinkering in the garage - tuning CARs for safety. *Nature Reviews Clinical Oncology*, **2019**, 16, 530-532	19.4	
70	Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. *Cancer Cell*, **2019**, 35, 489-503.e8	24.3	123
69	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. *Blood*, **2019**, 133, 1652-1663	2.2	158

68	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. *Blood*, **2019**, 134, 636-640	2.2	89
67	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. *Blood*, **2019**, 133, 1876-1887	2.2	126
66	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. *Blood Advances*, **2019**, 3, 3590-3601	7.8	27
65	Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. *Journal of Immunology*, **2019**, 202, 476-483	5.3	27
64	Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. *Journal of Immunology*, **2018**, 200, 459-468	5.3	109
63	Chimeric antigen receptor-modified T cells: CD19 and the road beyond. *Blood*, **2018**, 131, 2621-2629	2.2	96
62	Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. *Cancer Discovery*, **2018**, 8, 750-763	24.4	136
61	Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 242-251	4.7	46
60	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. *Blood*, **2018**, 131, 121-130	2.2	225
59	Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. *Science Signaling*, **2018**, 11,	8.8	192
58	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. *Blood*, **2018**, 132, 1011-1011	2.2	62
57	Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. *Blood*, **2017**, 129, 3322-3331	2.2	582
56	Therapeutic T cell engineering. *Nature*, **2017**, 545, 423-431	50.4	420
55	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. *Cancer Discovery*, **2017**, 7, 1404-1419	24.4	649
54	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. *Journal of Clinical Oncology*, **2017**, 35, 3010-3020	2.2	396
53	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood*, **2017**, 130, 2295-2306	2.2	522
52	Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. *Clinical Cancer Research*, **2017**, 23, 3061-3071	12.9	89
51	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. *Science Translational Medicine*, **2016**, 8, 355ra116	17.5	613

50	Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. *Cancer Immunology Research*, **2016**, 4, 509-19	12.5	16
49	Role of memory T cell subsets for adoptive immunotherapy. *Seminars in Immunology*, **2016**, 28, 28-34	10.7	129
48	Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. *Nature Biotechnology*, **2016**, 34, 430-4	44.5	42
47	Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. *Journal of Clinical Investigation*, **2016**, 126, 4262-4272	15.9	162
46	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 56-56	2.2	10
45	Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo. *Oncotarget*, **2016**, 7, 43267-43280	3.3	12
44	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *Journal of Clinical Investigation*, **2016**, 126, 2123-38	15.9	1143
43	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. *Blood*, **2016**, 127, 2406-10	2.2	436
42	Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. *Blood*, **2016**, 127, 2980-90	2.2	191
41	Engineering CAR-T cells: Design concepts. *Trends in Immunology*, **2015**, 36, 494-502	14.4	247
40	Adoptive cellular therapy: a race to the finish line. *Science Translational Medicine*, **2015**, 7, 280ps7	17.5	252
39	A BiTE from cancer's intracellular menu. *Nature Biotechnology*, **2015**, 33, 1040-1	44.5	3
38	The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. *Cancer Immunology Research*, **2015**, 3, 125-35	12.5	294
37	Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. *Cancer Immunology Research*, **2015**, 3, 206-16	12.5	112
36	Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. *Journal of Clinical Investigation*, **2015**, 125, 2677-89	15.9	191
35	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. *Blood*, **2015**, 126, 184-184	2.2	36
34	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 3773-3773	2.2	29
33	Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. *Immunity*, **2014**, 41, 116-26	32.3	203

32	Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 705-16	4.7	75
31	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells **2014**, 2, 36		45
30	Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. *Immunological Reviews*, **2014**, 257, 127-44	11.3	109
29	Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. *PLoS ONE*, **2014**, 9, e96565	3.7	81
28	Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. *Clinical Cancer Research*, **2013**, 19, 3153-64	12.9	330
27	TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. *Science Translational Medicine*, **2013**, 5, 192ra87	17.5	69
26	Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. *PLoS ONE*, **2013**, 8, e82742	3.7	132
25	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. *Blood*, **2012**, 119, 3940-50	2.2	396
24	Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. *Blood*, **2012**, 119, 72-82	2.2	152
23	The Non-Signaling Extracellular Spacer Domain of CD19-Specific Chimeric Antigen Receptors Is Decisive for in Vivo Anti-Tumor Activity. *Blood*, **2012**, 120, 951-951	2.2	3
22	Novel serial positive enrichment technology enables clinical multiparameter cell sorting. *PLoS ONE*, **2012**, 7, e35798	3.7	50
21	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. *Blood*, **2011**, 118, 1255-63	2.2	382
20	Cytomegalovirus-Specific T Cells Are Elicited Early After Umbilical Cord Blood Transplant but Fail to Expand In Vivo and Control Virus Replication. *Blood*, **2011**, 118, 1974-1974	2.2	
19	Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. *Blood*, **2010**, 115, 3869-78	2.2	188
18	Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. *Blood*, **2010**, 115, 4923-33	2.2	85
17	The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. *Blood*, **2010**, 116, 4532-41	2.2	200
16	Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. *Journal of Clinical Investigation*, **2008**, 118, 294-305	15.9	633
15	Viral Genome Scan for Analysis of CMV-Specific CD8+ T Cells in Normal and Immunocompromised Individuals.. *Blood*, **2007**, 110, 1068-1068	2.2	1

14	Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells.. *Blood*, **2007**, 110, 499-499	2.2	0
13	Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.. *Blood*, **2006**, 108, 413-413	2.2	
12	Human Minor Histocompatibility Antigen-Specific CD8+ T Cells Are Found Predominantly in the CD45RA+ CD62L+ Nai ve T Cell Subset.. *Blood*, **2005**, 106, 578-578	2.2	6
11	Increased Risk for Treatment-Related Mortality of Bone Marrow Transplantation in GSTM1-Positive Recipients.. *Blood*, **2005**, 106, 1756-1756	2.2	
10	Finding a place for tumor-specific T cells in targeted cancer therapy. *Journal of Experimental Medicine*, **2004**, 200, 1533-7	16.6	22
9	Impact of Homozygous Deletion of UGT2B17 on Outcome of Allogeneic BMT.. *Blood*, **2004**, 104, 1837-1837	2.2	
8	IL15, but Not IL2, Supports Long-Term Survival and Function of Human and Macaque Antigen-Specific CD8+ T Cell Clones.. *Blood*, **2004**, 104, 3237-3237	2.2	
7	T-cell therapy of leukemia. *Cancer Control*, **2002**, 9, 114-22	2.2	30
6	Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. *Nature Immunology*, **2001**, 2, 255-60	19.1	791
5	Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. *Journal of Experimental Medicine*, **2000**, 192, 1637-44	16.6	374
4	A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. *Science*, **1997**, 277, 1306-9	33.3	436
3	Principles for adoptive T cell therapy of human viral diseases. *Annual Review of Immunology*, **1995**, 13, 545-86	34.7	214
2	Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *New England Journal of Medicine*, **1995**, 333, 1038-44	59.2	1563
1	The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. *Journal of Immunological Methods*, **1990**, 128, 189-201	2.5	298